Managing Severe Community-Acquired Pneumonia Due to Community Methicillin-Resistant Staphylococcus aureus (MRSA). (Q43636170)

25 November 2017

title

Managing Severe Community-Acquired Pneumonia Due to Community Methicillin-Resistant Staphylococcus aureus (MRSA). (English)

1 reference

methicillin-resistant Staphylococcus aureus

25 November 2017

main subject

0 references

pneumonia

1 reference

inferred from title

Staphylococcus aureus

1 reference

1

1 reference

25 November 2017

Kyra Chua

2

1 reference

25 November 2017

Patrick G P Charles

series ordinal

3

1 reference

25 November 2017

publication date

1 June 2012

1 reference

Current infectious disease reports

25 November 2017

published in

1 reference

25 November 2017

volume

14

1 reference

25 November 2017

issue

3

1 reference

25 November 2017

page(s)

330-338

1 reference

The etiology of community-acquired pneumonia in Australia: why penicillin plus doxycycline or a macrolide is the most appropriate therapy

25 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS11908-012-0254-8

Emergence of community-acquired meticillin-resistant Staphylococcus aureus strain USA300 as a cause of necrotising community-onset pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-012-0254-8

The dominant Australian community-acquired methicillin-resistant Staphylococcus aureus clone ST93-IV [2B] is highly virulent and genetically distinct

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-012-0254-8

Comparative analysis of virulence and toxin expression of global community-associated methicillin-resistant Staphylococcus aureus strains

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-012-0254-8

Antimicrobial resistance: Not community-associated methicillin-resistant Staphylococcus aureus (CA-MRSA)! A clinician's guide to community MRSA - its evolving antimicrobial resistance and implications for therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-012-0254-8

Severe community-onset pneumonia in healthy adults caused by methicillin-resistant Staphylococcus aureus carrying the Panton-Valentine leukocidin genes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-012-0254-8

Association between Staphylococcus aureus strains carrying gene for Panton-Valentine leukocidin and highly lethal necrotising pneumonia in young immunocompetent patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-012-0254-8

Severe community-acquired pneumonia due to Staphylococcus aureus, 2003-04 influenza season

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-012-0254-8

Expanded clinical presentation of community-acquired methicillin-resistant Staphylococcus aureus pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-012-0254-8

Community-acquired pneumonia due to pandemic A(H1N1)2009 influenzavirus and methicillin resistant Staphylococcus aureus co-infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-012-0254-8

Community-associated meticillin-resistant Staphylococcus aureus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-012-0254-8

Community-acquired methicillin-resistant Staphylococcus aureus: the role of Panton-Valentine leukocidin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-012-0254-8

Staphylococcus aureus Panton-Valentine leukocidin causes necrotizing pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-012-0254-8

Staphylococcus aureus panton-valentine leukocidin is a very potent cytotoxic factor for human neutrophils

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-012-0254-8

Is Panton-Valentine leukocidin the major virulence determinant in community-associated methicillin-resistant Staphylococcus aureus disease?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-012-0254-8

Polymorphonuclear leukocytes mediate Staphylococcus aureus Panton-Valentine leukocidin-induced lung inflammation and injury.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-012-0254-8

Poring over pores: alpha-hemolysin and Panton-Valentine leukocidin in Staphylococcus aureus pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-012-0254-8

Complete genome sequence of USA300, an epidemic clone of community-acquired meticillin-resistant Staphylococcus aureus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-012-0254-8

The arginine catabolic mobile element is not associated with enhanced virulence in experimental invasive disease caused by the community-associated methicillin-resistant Staphylococcus aureus USA300 genetic background

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-012-0254-8

The arginine catabolic mobile element and staphylococcal chromosomal cassette mec linkage: convergence of virulence and resistance in the USA300 clone of methicillin-resistant Staphylococcus aureus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-012-0254-8

Impact of Gram-positive resistance on outcome of nosocomial pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-012-0254-8

Bacteremic pneumonia due to Staphylococcus aureus: A comparison of disease caused by methicillin-resistant and methicillin-susceptible organisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-012-0254-8

Clinical management of Staphylococcus aureus bacteraemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-012-0254-8

Persistent Staphylococcus aureus bacteremia: incidence and outcome trends over time

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-012-0254-8

The role of vancomycin in the persistence or recurrence of Staphylococcus aureus bacteraemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-012-0254-8

Predictors of mortality for methicillin-resistant Staphylococcus aureus health-care-associated pneumonia: specific evaluation of vancomycin pharmacokinetic indices

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-012-0254-8

Penetration of vancomycin into human lung tissue

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-012-0254-8

Analysis of vancomycin entry into pulmonary lining fluid by bronchoalveolar lavage in critically ill patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-012-0254-8

Pharmacodynamics of vancomycin at simulated epithelial lining fluid concentrations against methicillin-resistant Staphylococcus aureus (MRSA): implications for dosing in MRSA pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-012-0254-8

Antimicrobial treatment of nosocomial meticillin-resistant Staphylococcus aureus (MRSA) pneumonia: current and future options

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-012-0254-8

Good clinical outcomes but high rates of adverse reactions during linezolid therapy for serious infections: a proposed protocol for monitoring therapy in complex patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-012-0254-8

Linezolid (PNU-100766) versus vancomycin in the treatment of hospitalized patients with nosocomial pneumonia: a randomized, double-blind, multicenter study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-012-0254-8

Continuation of a randomized, double-blind, multicenter study of linezolid versus vancomycin in the treatment of patients with nosocomial pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-012-0254-8

Linezolid and vancomycin for methicillin-resistant Staphylococcus aureus nosocomial pneumonia: the subtleties of subgroup analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-012-0254-8

Unresolved questions with the use of linezolid vs vancomycin for nosocomial pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-012-0254-8

Improved outcomes with linezolid for methicillin-resistant Staphylococcus aureus infections: better drug or reduced vancomycin susceptibility?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-012-0254-8

Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-012-0254-8

Reduced vancomycin susceptibility in Staphylococcus aureus, including vancomycin-intermediate and heterogeneous vancomycin-intermediate strains: resistance mechanisms, laboratory detection, and clinical implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-012-0254-8

Linezolid versus vancomycin or teicoplanin for nosocomial pneumonia: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-012-0254-8

Infectious Diseases Society of America/American Thoracic Society Consensus Guidelines on the Management of Community-Acquired Pneumonia in Adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-012-0254-8

Guidelines for UK practice for the diagnosis and management of methicillin-resistant Staphylococcus aureus (MRSA) infections presenting in the community

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-012-0254-8

Disparity between timed-kill and checkerboard methods for determination of in vitro bactericidal interactions of vancomycin plus rifampin versus methicillin-susceptible and -resistant Staphylococcus aureus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-012-0254-8

In-vitro effects of vancomycin, rifampicin, and fusidic acid, alone and in combination, against methicillin-resistant Staphylococcus aureus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-012-0254-8

Effect of vancomycin plus rifampicin in the treatment of nosocomial methicillin-resistant Staphylococcus aureus pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-012-0254-8

Multiple combination bactericidal testing of staphylococcal biofilms from implant-associated infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-012-0254-8

Emergence of resistance among USA300 methicillin-resistant Staphylococcus aureus isolates causing invasive disease in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-012-0254-8

Clindamycin treatment of methicillin-resistant Staphylococcus aureus infections in children

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-012-0254-8

Pleuropulmonary complications of Panton-Valentine leukocidin-positive community-acquired methicillin-resistant Staphylococcus aureus: importance of treatment with antimicrobials inhibiting exotoxin production

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-012-0254-8

In vitro activities of linezolid combined with other antimicrobial agents against Staphylococci, Enterococci, Pneumococci, and selected gram-negative organisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-012-0254-8

Limitations of antibiotic options for invasive infections caused by methicillin-resistant Staphylococcus aureus: is combination therapy the answer?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-012-0254-8

Activity of moxifloxacin in combination with vancomycin or teicoplanin against Staphylococcus aureus isolated from device-associated infections unresponsive to glycopeptide therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-012-0254-8

Vancomycin in combination with other antibiotics for the treatment of serious methicillin-resistant Staphylococcus aureus infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-012-0254-8

In vitro bactericidal activities of linezolid in combination with vancomycin, gentamicin, ciprofloxacin, fusidic acid, and rifampin against Staphylococcus aureus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-012-0254-8

Oral rifampin plus ofloxacin for treatment of Staphylococcus-infected orthopedic implants

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-012-0254-8

Trimethoprim-sulfamethoxazole compared with vancomycin for the treatment of Staphylococcus aureus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-012-0254-8

In vitro and in vivo assessment of linezolid combined with ertapenem: a highly synergistic combination against methicillin-resistant Staphylococcus aureus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-012-0254-8

In vitro and in vivo synergistic activities of linezolid combined with subinhibitory concentrations of imipenem against methicillin-resistant Staphylococcus aureus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-012-0254-8

In vitro activity of linezolid alone and in combination with gentamicin, vancomycin or rifampicin against methicillin-resistant Staphylococcus aureus by time-kill curve methods

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-012-0254-8

Ceftaroline fosamil: a novel broad-spectrum cephalosporin with activity against methicillin-resistant Staphylococcus aureus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-012-0254-8

Inhibition of daptomycin by pulmonary surfactant: in vitro modeling and clinical impact

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-012-0254-8

Development of daptomycin-susceptible, methicillin-resistant Staphylococcus aureus pneumonia during high-dose daptomycin therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-012-0254-8

Panton-Valentine leukocidin expressing Staphylococcus aureus pneumonia managed with extracorporeal membrane oxygenation: experience and outcome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-012-0254-8

Neutralization of Staphylococcus aureus Panton Valentine leukocidin by intravenous immunoglobulin in vitro.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-012-0254-8

Disseminated sepsis due to a Panton-Valentine leukocidin producing strain of community acquired meticillin resistant Staphylococcus aureus and use of intravenous immunoglobulin therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-012-0254-8

Prompt and successful toxin-targeting treatment of three patients with necrotizing pneumonia due to Staphylococcus aureus strains carrying the Panton-Valentine leukocidin genes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-012-0254-8

Effect of antibiotics on Staphylococcus aureus producing Panton-Valentine leukocidin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-012-0254-8

Beta-lactams interfering with PBP1 induce Panton-Valentine leukocidin expression by triggering sarA and rot global regulators of Staphylococcus aureus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-012-0254-8

Life-threatening community-acquired methicillin-resistant Staphylococcus aureus infection in Australia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-012-0254-8

Nasal carriage as a source of Staphylococcus aureus bacteremia. Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-012-0254-8

Reduction in incidence of nosocomial methicillin-resistant Staphylococcus aureus (MRSA) infection in an intensive care unit: role of treatment with mupirocin ointment and chlorhexidine baths for nasal carriers of MRSA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-012-0254-8

Prevalence of nasal colonization among patients with community-associated methicillin-resistant Staphylococcus aureus infection and their household contacts

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-012-0254-8

Factors Predicting Mortality in Necrotizing Community-Acquired Pneumonia Caused by Staphylococcus aureus Containing Panton-Valentine Leukocidin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-012-0254-8

New antimicrobial agents for methicillin-resistant Staphylococcus aureus

21 January 2018

1 reference

12 December 2020

Linezolid in Methicillin-Resistant Staphylococcus aureus Nosocomial Pneumonia: A Randomized, Controlled Study

1 reference

12 December 2020

Community-acquired methicillin-resistant Staphylococcus aureus pneumonia and ARDS: 1-year follow-up

1 reference

12 December 2020

Linezolid vs vancomycin: analysis of two double-blind studies of patients with methicillin-resistant Staphylococcus aureus nosocomial pneumonia

1 reference

12 December 2020

The bactericidal effects of anti-MRSA agents with rifampicin and sulfamethoxazole-trimethoprim against intracellular phagocytized MRSA

1 reference

12 December 2020

In vitro evaluation of clindamycin in combination with oxacillin, rifampin, or vancomycin against Staphylococcus aureus

1 reference

12 December 2020

In vitro activity of beta-lactam antibiotics to community-associated methicillin-resistant Staphylococcus aureus (CA-MRSA)

1 reference

12 December 2020

Fatal necrotising pneumonia due to community-acquired methicillin-resistant Staphylococcus aureus (MRSA).

1 reference

12 December 2020

Trimethoprim-sulfamethoxazole for the prevention of methicillin-resistant Staphylococcus aureus pneumonia in severely burned patients

1 reference

12 December 2020

BTS guidelines for the management of community acquired pneumonia in adults: update 2009

1 reference

12 December 2020

Guidelines for the prevention and management of community-associated methicillin-resistant Staphylococcus aureus: A perspective for Canadian health care practitioners

1 reference

12 December 2020

Community-acquired, methicillin-resistant Staphylococcus aureus isolated from children with community-onset pneumonia in China

1 reference

12 December 2020

Effects of subinhibitory concentrations of antibiotics on alpha-toxin (hla) gene expression of methicillin-sensitive and methicillin-resistant Staphylococcus aureus isolates

1 reference

12 December 2020

Community-acquired pneumonia

1 reference

12 December 2020

Impact of antibiotics on expression of virulence-associated exotoxin genes in methicillin-sensitive and methicillin-resistant Staphylococcus aureus

1 reference

12 December 2020

Microbial aetiology of community-acquired pneumonia and its relation to severity

1 reference

12 December 2020

10.1007/S11908-012-0254-8

Identifiers

DOI

1 reference

25 November 2017

1 reference